ADMA Biologics (NASDAQ:ADMA) Hits New 52-Week High at $18.58

ADMA Biologics, Inc. (NASDAQ:ADMA) hit a new 52-week high during trading on Monday . The stock traded as high as $18.58 and last traded at $18.58, with a volume of 13833 shares. The stock had previously closed at $18.40.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ADMA. Mizuho lifted their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Cantor Fitzgerald increased their target price on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Raymond James raised their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. Finally, HC Wainwright upped their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Trading Down 0.6 %

The company has a market capitalization of $4.02 billion, a PE ratio of -867.50 and a beta of 0.55. The company has a fifty day simple moving average of $13.47 and a 200-day simple moving average of $9.43. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The firm had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. ADMA Biologics’s quarterly revenue was up 78.4% on a year-over-year basis. Analysts predict that ADMA Biologics, Inc. will post 0.35 EPS for the current year.

Insider Transactions at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. Insiders sold 396,889 shares of company stock worth $6,358,166 in the last 90 days. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds have recently bought and sold shares of the company. Mesirow Institutional Investment Management Inc. purchased a new stake in ADMA Biologics during the first quarter worth about $17,221,000. Bank of Montreal Can acquired a new position in shares of ADMA Biologics in the second quarter valued at approximately $17,886,000. D. E. Shaw & Co. Inc. increased its stake in ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after buying an additional 1,442,799 shares during the period. Rice Hall James & Associates LLC purchased a new stake in ADMA Biologics during the 1st quarter worth approximately $7,963,000. Finally, Castleark Management LLC acquired a new stake in ADMA Biologics during the 1st quarter worth approximately $5,400,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.